

New Generation Medication Tracking

Introduction

New generation medications are an *exceptional* class of antipsychotic drugs. Persons in the DSHS and DADS service delivery system who receive new generation medication therapy are tracked as a subsystem of the Client Assignment and Registration (CARE) system.

The CARE system originally tracked only persons being prescribed one of these drugs, *Clozapine*. The tracking of persons receiving Clozapine therapy was referred to as Clozaril Tracking.

As more new generation medications have been developed and their use has been prescribed, CARE began tracking persons who were starting:

- *Clozaril drug therapy* effective 1999 or earlier
- *Risperidone drug therapy* effective September 1, 1996
- *Olanzapine drug therapy* effective October 25, 1996
- *Quetiapine drug therapy* effective November 1, 1997
- *Generic Clozapine drug therapy* effective June 1, 1999
- *Ziprasidone drug therapy* effective April 1, 2001
- *Aripiprazole drug therapy* effective November 19, 2002
- *Risperdal Consta therapy* effective January 14, 2004
- *Invega (Paliperidone) therapy* effective April 3, 2007
- *Invega Sustenna therapy* effective September 25, 2009
- *Saphris therapy* effective January 29, 2010
- *Fanapt* effective April 9, 2010
- *Relprevv* effective July 9, 2010
- *Lurasidone* effective April 1, 2011
- *Aripiprazole LAI* effective July 12, 2013

As the development of future new generation medications occurs, some of these may be added to the CARE system tracking.

As of June 1, 2002, multiple new generation medications can be reported. Different drugs from different components can be used with overlapping dates, but the same drug *cannot* be used with overlapping dates at the same component.

CARE

Action Codes

Action Codes 375 and 795 are used in CARE to allow:

- tracking of persons being prescribed Clozapine, Risperidone, Olanzapine, Quetiapine, Generic Clozapine, Ziprasidone, Aripiprazole Risperdal Consta *or*, Invega, Invega Sustenna, Saphris, Fanapt, Relprevv, Lurasidone, and Aripiprazole LAI
- production of a listing of persons who receive new generation medications at your component

Following is a brief overview of Actions Codes 375 and 795. Complete procedures for using these Action Codes and the screens they access are included in this documentation.

continued on next page

New Generation Medication Tracking, Continued

Action Code 375 Procedures are alike for tracking persons who receive new generation medication therapy, i.e., Clozapine, Risperidone, Olanzapine, Quetiapine, Generic Clozapine, Ziprasidone, Aripiprazole, Risperdal Consta, Invega, Invega Sustenna, Saphris, Fanapt, Relprevv, Lurasidone, Aripiprazole LAI or any other new generation medication, using the 375: New Generation Medication Tracking: Add/Change/Delete screen.

When a person at your component begins new generation medication therapy, you must use the 375: New Generation Medication Tracking: Add/Change/Delete screen to enter the FUNDING SOURCE and START DATE.

When a person at your component discontinues the drug therapy, you must use the 375: New Generation Medication Tracking: Add/Change/Delete screen to enter the END DATE, END REASON, and NEXT COMP (destination component), if appropriate.

The 375: New Generation Medication Tracking: Add/Change/Delete screen also tracks the Case Administering Component. By adding your component's case number and start date, your component becomes the case administrator.

Action Code 795 You can obtain a list of persons at your component who receive new generation medications by using 795: New Generation Medication Tracking Report to produce a report.

Guidelines for Entering a Funding Source for Persons Prescribed New Generation Medications

Introduction

When a person receiving a new generation medication is entered into the CARE system, an appropriate funding source must also be entered. The following are guidelines to use for determining the appropriate funding source. These guidelines are effective as of 9/1/95 for Clozapine procedures, 9/1/96 for Risperidone, 10/25/96 for Olanzapine, 11/1/97 for Quetiapine, 6/1/99 for Generic Clozapine, 4/1/01 for Ziprasidone, 11/19/02 for Aripiprazole, 1/14/04 for Risperdal Consta, 4/3/07 for Invega, 9/25/09 for Invega Sustenna, 1/29/10 for Saphris, 4/09/10 for Fanapt, 7/9/2010 for Relprevv, and 4/1/2011 for Lurasidone and 7/12/2013 for Aripiprazole LAI.

Note: If the funding source changes, you must enter an END DATE and add a *new* record with the *new* FUNDING SOURCE.

Funding Source 1: Hospital In-Patient - 74th/HB1

As a State Hospital or State Center starting a person on a new generation medication, use this Funding Source, regardless of the patient's status of voluntary or involuntary commitment.

Keep your Business Office apprised through the pharmacy.

Funding Source 2: State Campus Facility Pay

As a State Hospital, State Center, or State School, use this funding source to indicate that *your* campus or center will be paying for the costs of the new generation medications and the monitoring of those medications from *your* operating budget.

Funding Source 4: Other

Use this funding source for persons in the community who are funded by some other method, such as:

- third party insurance
 - private pay, *or*
 - from non-new generation medication funds within the community center operating budget.
-

Funding Source 6: MHMR Community Only

Use this funding source for non-Medicaid consumers paid from new generation medication appropriated funds.

Guidelines for Entering a Funding Source for Persons Prescribed New Generation Medications, Continued

Funding Source M: Use this funding source for persons in the community who are Medicaid eligible but get their prescriptions through a private pharmacy that is reimbursed directly from Medicaid.
Other Medicaid

A match of CARE data with the DADS Medicaid file is run Monday and Thursday nights that checks all persons open for general revenue payment of new generation medications and for those with fund source equal to 3 or 6 the system changes that fund source to M. When a client's Medicaid eligibility stops, it is the center's responsibility to provide the appropriate funding source in CARE.

Funding Source 7: This funding source is only used in special circumstances for Medicaid-eligible consumers with the center providing the medications from a vendor drug pharmacy that it operates. Funding Source 7 may only be used on an exception basis. If your center has a vendor drug pharmacy and you feel that you have some extenuating circumstances which require the use of Funding Source 7, please contact your Contract Manager.
**Medicaid
Community Only**

Funding Source 8: Use this funding source for all free new generation medications, including coupons, samples, and drugs provided through assistance programs for indigent consumers.
Free New Generation Medications

Community and Facility

At the time free medication ends, you will be responsible for making the changes in CARE to end Funding Source 8 and add the new funding source as appropriate. Entries should be made on the 375 screen in CARE (New Generation Medication Tracking: Add/Change/Delete).

Funding Source 9: Use this funding source if the consumer has Medicare Part D coverage and when the NGMs costs are subsidized by general revenue.
**Medicare Part D
Community**

Funding Source D: Use this funding source for Medicare Part D if the consumer is paying his/her own co-pay and premium. This funding source can be used for the dual eligible.
**Medicare Part D
Community**

Guidelines for Entering a Funding Source for Persons Prescribed New Generation Medications, Continued

Community Program Note:

To open a New Generation Medication tracking on the 375 screen, consumer must have an open campus or community assignment or an authorized RDM assessment in CARE.

Intranet Site

The Intranet site for New Generation Medications is

<http://www2.hhsc.state.tx.us/CentralOffice/MedicalDirector/dsmco2.htm>

This site includes a listing of clients who are taking new generation medications with non-psychotic diagnoses not appropriate for reimbursement. This site is updated weekly. The DSM codes appropriate for reimbursement are part of this site.

375: New Generation Medication Tracking: Add/Change/Delete

Introduction

The 375: New Generation Medication Tracking: Add/Change/Delete screen allows you to access the screens that are used to add, change, or delete information concerning persons who receive reimbursement for new generation medication therapy.

How to Access

To access the 375: New Generation Medication Tracking: Add/Change/Delete request screen:

1. Key **375** in the ACT: field of any screen.
2. Press **<Enter>**.

Result: The request screen is displayed.

Request Screen

The 375: New Generation Medication Tracking: Add/Change/Delete request screen is shown below.

```
04-13-07 375:NEW GENERATION MEDICATION TRACKING: ADD/CHANGE/DELETE  VC027770

      PLEASE ENTER THE FOLLOWING:

COMPONENT CODE/LOCAL CASE NUMBER:      /

      PLEASE ENTER THE FOLLOWING:

TYPE OF ENTRY                           :      (A/ADD,C/CHANGE,D/DELETE)

                                     *** PRESS ENTER ***

ACT:      (300/DATA ENTRY MENU, M/MENU)
```

375: New Generation Medication Tracking: Add/Change/Delete, Continued

Screen Field Table The table describes the fields as they are displayed on the screen.

Field	Contents		
COMPONENT CODE	Your component code is supplied by CARE based on your logon account number.		
LOCAL CASE NUMBER	Key the person's local case number issued at your component.		
TYPE OF ENTRY	Select an option.		
	If you want to...	then key...	Result
	add new data	A and press <Enter>.	The <u>375: New Generation Medication Tracking: Add</u> screen is displayed.
	change data	C and press <Enter>.	The <u>375: New Generation Medication Tracking: Change</u> screen is displayed.
	delete data	D and press <Enter>.	The <u>375: New Generation Medication Tracking: Delete</u> screen is displayed.

Record Search The system searches for records.

If...	and...	then...
a record is found	— —	the requested screen is displayed.
no record is found	the message " <i>Local Case Number Not Found</i> " is displayed	check the local case number to see if it was keyed correctly.
no record is found	the local case number was keyed correctly	you <i>cannot</i> use this function because the person has not been registered into the CARE system.

375: New Generation Medication Tracking: Add

Add Screen

The 375: New Generation Medication Tracking: Add screen is used to indicate that a person is beginning new generation medication therapy. **An old sample screen is shown below.** Currently only the codes are listed as space was not available – to see decodes enter “H” in ACT field.

```
04-13-07      375:NEW GENERATION MEDICATION TRACKING: ADD      VC027775
                                                    1 OF 1
LAST NAME/SUF: BIRCH      CLIENT ID      : 11835
FIRST NAME   : BENT      LOCAL CASE NUMBER : 0000059509
MIDDLE NAME  : J        COMPONENT      : 677

DRUG START DATE FUNDING END DATE END      NEXT
TYPE MMDDYYYY  SOURCE  MMDDYYYY REASON  COMMENT      COMP

DRUG TYPE      FUNDING SOURCE CODES      REASON FOR ENDING CODES
-----
GC=GENERIC CLOZ      1-HOSPITAL IN-PATNT-74TH/HB1 1-NO OR POOR RESPONSE
C=CLOZARIL/I=INVEGA  2-STATE CAMPUS FACILITY PAY  2-DECREASED WBC
R=RISPERIDONE      4-OTHER      3-SIDE EFFECT OTH THAN WBC
O=OLANZAPINE      6-MHMR COMMUN ONLY  4-LOSS OF FUNDING
Q=QUETIAPINE      M-OTHER MEDICAID      5-OTHER
Z=ZIPRASIDONE      7-MEDICAID COMMUN ONLY
A=ARIPIPIRAZOLE      8-FREE
RC=RISPERDAL CONSTA  9-MEDICARE PART D      D-PART D SELF PAY
READY TO ADD?      :  _ (Y/N)

ACT:      (300/DATA ENTRY MENU, M/MENU)
```

Funding Source Codes

A one-digit code is used to indicate the source of funding for the drug therapy. Refer to *Guidelines for Entering a Funding Source for Persons Prescribed New Generation Medications* for a listing of the Funding Source codes and descriptions.

375: New Generation Medication Tracking: Add, Continued

Screen Field Table The table describes the fields as they are displayed on the screen.

Field	Contents
LAST NAME/ SUF	Person's last name and (optional) suffix. (e.g., Jr, Sr)
FIRST NAME	Person's first name.
MIDDLE NAME	Person's middle name.
CLIENT ID	Person's statewide identification number assigned by CARE.
LOCAL CASE NUMBER	Person's local case number assigned by the component.
COMPONENT	Three-digit code of the component dispensing the new generation medication.
DRUG TYPE	Key the code indicating the drug type the person will be receiving. (GC=Generic Clozapine, C=Clozaril, R=Risperidone, O=Olanzapine, Q=Quetiapine, Z=Ziprasidone, A=Aripiprazole, RC=Risperdal Consta, I = Invega or P = Paliperidone); IS = Invega Sustenna, SP = Saphris, FA = Fanapt, RL = Relprevv, LU = Lurasidone, AL = Aripiprazole LAI
START DATE MMDDYYYY	Key the date the person started receiving the drug. MMDDYYYY format.
FUNDING SOURCE	Key the one-digit code indicating the source of funding for the drug therapy.
END DATE MMDDYYYY	Date the person stopped receiving the drug therapy. (Not applicable-only used when ending drug therapy.)
END REASON	One-digit code that explains why the person has stopped receiving the drug therapy. (Not applicable-only used when ending drug therapy.)
COMMENT	Text to describe the reason for ending the drug therapy. (Not applicable-only used when ending drug therapy.)
NEXT COMP	Three-digit code of the component to which the person is transferring. (Not applicable-only used when transferring a person.)

READY TO ADD?

Use the READY TO ADD? field to determine the action you want to take.

If you want to	then key...	Result
submit the data to the system	Y and press <Enter>.	The <u>375: New Generation Medication Tracking</u> request screen is displayed with the message "Previous Information Added."
cancel your request to add data	N and press <Enter>.	The <u>375: New Generation Medication Tracking</u> request screen is displayed.
cancel your request to add data <i>and</i> branch to another function	<ul style="list-style-type: none"> • N • an action code in the ACT: field • press <Enter>. 	You are taken to the screen defined by the action code you entered.

375: New Generation Medication Tracking: Change

Changing New Generation Medication Information

Most changes to previously added new generation medication information can be made using the 375: New Generation Medication Tracking: Change screen.

Funding Source

Refer to *Guidelines for Entering a Funding Source for Persons Prescribed New Generation Medications* for a listing of the Funding Source codes and descriptions.

FUNDING SOURCE *cannot* be “changed”.

If...	then you...
an error was made in the FUNDING SOURCE field	<i>must</i> delete the record and re-enter the correct data.
the funding source changes	<i>must</i> enter an end date and add a record with the new funding source.

Change Screen

An old sample 375: New Generation Medication Tracking: Change screen is shown below. Currently only the codes are listed as space was not available – to see decodes enter “H” in ACT field.

```

04-13-07      375:NEW GENERATION MEDICATION TRACKING: CHANGE      VC027775
                                                    1 OF 2
LAST NAME/SUF: BIRCH                CLIENT ID      : 11835
FIRST NAME  : BENT                  LOCAL CASE NUMBER : 0000059509
MIDDLE NAME : J                    COMPONENT      : 677

DRUG START DATE FUNDING END DATE END      NEXT
TYPE MMDDYYYY  SOURCE MMDDYYYY REASON  COMMENT      COMP
                1

DRUG TYPE          FUNDING SOURCE CODES      REASON FOR ENDING CODES
-----
GC=GENERIC CLOZ    1-HOSPITAL IN-PATNT-74TH/HB1 1-NO OR POOR RESPONSE
C=CLOZARIL/I=INVEGA 2-STATE CAMPUS FACILITY PAY 2-DECREASED WBC
R=RISPERIDONE      4-OTHER                          3-SIDE EFFECT OTH THAN WBC
O=OLANZAPINE       6-MHMR COMMUN ONLY              4-LOSS OF FUNDING
Q=QUETIAPINE       M-OTHER MEDICAID                5-OTHER
Z=ZIPRASIDONE      7-MEDICAID COMMUN ONLY
A=ARIPIPRAZOLE     8-FREE
RC=RISPERDAL CONSTA 9-MEDICARE PART D              D-PART D SELF PAY
READY TO CHANGE?   : _ (Y/N)

ACT:                (300/DATA ENTRY MENU, M/MENU)
    
```

375: New Generation Medication Tracking: Change

Change Fields

Current data is displayed on the 375: New Generation Medication Tracking: Change screen, including the DRUG TYPE.

The following table describes the fields that can be changed.

Field	Contents
DRUG TYPE	Key the code indicating the drug type the person is receiving. (GC=Generic Clozapine, C=Clozaril, R=Risperidone, O=Olanzapine, Q=Quetiapine, Z=Ziprasidone, A=Aripiprazole, RC=Risperdal Consta, I= Invega or P = Paliperidone), IS = Invega Sustenna, SP = Saphris, FA = Fanapt, RL = Relprevv, LU = Lurasidone ; AL = Aripiprazole LAI
START DATE MMDDYYYY	Key the date the person started receiving new generation medications. MMDDYYYY format.
END DATE MMDDYYYY	Key the date the person stopped receiving new generation medications. MMDDYYYY format. <u>Rule:</u> If you key an End Date, you <i>must</i> key an End Reason.
END REASON	Key the one-digit code that explains why the person has stopped receiving new generation medications. 1 - No or Poor Response 2 - Decreased WBC 3 - Side Effect Other Than WBC 4 - Loss of Funding 5 - Other <u>Rule:</u> You <i>must</i> key an End Reason if you keyed an End Date.
COMMENT	Key text (up to 25 characters) to describe the reason for ending new generation medication therapy. <u>Rule:</u> If you key a Comment, you <i>must</i> key an End Date.
NEXT COMP	Key the three-digit code of the component to which the person is transferring, if applicable.

READY TO CHANGE?

Use the READY TO CHANGE? field to determine the action you want to take.

If you want to	then key...	Result
submit the data to the system	Y and press <Enter>.	The <u>375: New Generation Medication Tracking</u> request screen is displayed with the message "Previous Information Changed."
cancel your request to change data	N and press <Enter>.	The <u>375: New Generation Medication Tracking</u> request screen is displayed.
cancel your request to add data <i>and</i> branch to another function	<ul style="list-style-type: none"> • N • an action code in the ACT: field • press <Enter>. 	You are taken to the screen defined by the action code you entered.

375: New Generation Medication Tracking: Delete

Deleting New Generation Medication Information

The 375: New Generation Medication Tracking: Delete screen is used to delete new generation medication information.

Delete Screen

An old sample 375: New Generation Medication Tracking: Delete screen is shown below. Currently only the codes are listed as space was not available – to see decodes enter “H” in ACT field.

```

04-13-07      375:NEW GENERATION MEDICATION TRACKING: DELETE      VC027775
                                           1 OF 2
LAST NAME/SUF: BIRCH                      CLIENT ID       : 11835
FIRST NAME   : BENT                        LOCAL CASE NUMBER : 0000059509
MIDDLE NAME  : J                          COMPONENT      : 677

DRUG START DATE FUNDING END DATE END      NEXT
TYPE MMDDYYYY  SOURCE MMDDYYYY REASON  COMMENT      COMP
C_ 04222002    1      -      -      -      -

DRUG TYPE          FUNDING SOURCE CODES      REASON FOR ENDING CODES
-----
GC=GENERIC CLOZ    1-HOSPITAL IN-PATNT-74TH/HB1 1-NO OR POOR RESPONSE
C=CLOZARIL/I=INVEGA 2-STATE CAMPUS FACILITY PAY 2-DECREASED WBC
R=RISPERIDONE      4-OTHER                        3-SIDE EFFECT OTH THAN WBC
O=OLANZAPINE       6-MHMR COMMUN ONLY            4-LOSS OF FUNDING
Q=QUETIAPINE       M-OTHER MEDICAID              5-OTHER
Z=ZIPRASIDONE      7-MEDICAID COMMUN ONLY
A=ARIPIPRAZOLE     8-FREE
RC=RISPERDAL CONSTA 9-MEDICARE PART D            D-PART D SELF PAY
READY TO DELETE?   : _ (Y/N)

ACT:                (300/DATA ENTRY MENU, M/MENU)
    
```

Screen Field Table

Refer to the 375: New Generation Medication Tracking: Add screen field table for a description of the fields.

READY TO DELETE?

Use the READY TO DELETE? field to determine the action you want to take.

If you want to...	then key...	Result
delete the record	Y and press <Enter>.	The <u>375: New Generation Medication Tracking</u> request screen is displayed with the message “ <i>Previous Information Deleted.</i> ”
cancel your request to delete information	N and press <Enter>.	The <u>375: New Generation Medication Tracking</u> request screen is displayed.
cancel your request to delete data and branch to another function	<ul style="list-style-type: none"> • N • an action code in the ACT: field • press <Enter>. 	You are taken to the screen defined by the action code you entered.

795: New Generation Medication Tracking Report

Introduction

The 795: New Generation Medication Tracking Report is provided as an online report in CARE and allows you to produce a list of persons receiving new generation medications based on the component that started the drug therapy. The request screen is used to select criteria for the report.

How to Access

To access the request screen:

1. Key **795** in the ACT: field.
2. Press **<Enter>**.

Result: The request screen is displayed.

Request Screen

The 795: New Generation Medication Tracking Report request screen is shown below.

```
04-13-07      795:NEW GENERATION MEDICATION TRACKING REPORT      VC028920

PLEASE ENTER THE FOLLOWING TO DELIMIT REPORT:

      COMPONENT CODE      :
      LOCAL CASE NUMBER   :
      CLIENT ID           :
      DRUG TYPE (BLANK=ALL) :      (C=CLOZARIL, R=RISPERIDONE,
      FUNDING SOURCE      :      O=OLANZAPINE, Q=QUETIAPINE,
      REASON FOR ENDING   :      GC=GEN CLOZAP, RC=RISPER CONST
                               Z=ZIPRASIDONE, A=ARIPIRAZOLE,
                               I=INVEGA)
      PERIOD BEGIN DATE   :      PERIOD END DATE

      ENTER IF DESIRED:
      PRINTER CODE       :      (ENTER FOR HARD-COPY)

      *** PRESS ENTER ***

ACT:      (700/CARE REPORTING MENU, M/MENU)
```

795: New Generation Medication Tracking Report, Continued

Criteria Selection

For the field	You will ...
COMPONENT CODE	key the three-digit code of the billing component. <u>Example:</u> 030
LOCAL CASE NUMBER	key the person's local case number assigned by the component. <u>Rule:</u> If you key a local case number, you <i>must</i> key a component code.
CLIENT ID	key a valid statewide CARE identification number.
DRUG TYPE	key a code for the type of drug being prescribed <i>or</i> leave blank for <i>all</i> drug types. (C=Clozaril, R=Risperidone, O=Olanzapine, Q=Quetiapine, GC=Generic Clozapine, RC=Risperdal Consta, Z=Ziprasidone, A=Aripiprazole, I = Invega or P = Paliperidone), IS = Invega Sustenna, SP = Saphris, FA = Fanapt, RL = Relprevv, LU = Lurasidone , AL = Aripiprazole LAI
FUNDING SOURCE	key a one-digit funding source code. Valid codes are: <ul style="list-style-type: none"> • 1=Hospital In-Patient - 74th/HB1 • 2=State Campus Facility Pay • 4=Other • 6=MHMR Community Only • M=Other Medicaid • 7=Medicaid Community Only • 8=Free • 9=Medicare Part D • D=Part D Self Pay
REASON FOR ENDING	key a one-digit reason for ending code. Valid codes are: <ul style="list-style-type: none"> • 1=No or Poor Response • 2=Decreased WBC • 3=Side Effect Other Than WBC • 4=Loss of Funding • 5=Other
PERIOD BEGIN DATE	key the month, day, and year for which the report is to begin. <u>Rule:</u> Date <i>must</i> be in MMDDYY format.
PERIOD END DATE	key the month, day, and year for which the report is to end. <u>Rule:</u> Date <i>must</i> be in MMDDYY format.
PRINTER CODE	key the printer code for your printer if you want a hard copy of your report. <u>Note:</u> If you leave this field blank, the report will be displayed on your screen.

Submit Request

When you finish keying the selection criteria and you are ready to submit your request:

Press <Enter>.

Result: The 795: New Generation Medication Tracking System Report screen is displayed.

795: New Generation Medication Tracking System Report

Sample Report

A sample 795: New Generation Medication Tracking System Report screen is shown below. (All information shown in this example is fictitious.)

```
04-13-07 795:NEW GENERATION MEDICATION TRACKING SYSTEM REPORT 655/VCO28925
08:22 FROM 01-01-04 THRU 04-13-07 PAGE 1 OF 2 RECS

COMPONENT: 677 CASE NUMBER: 0000059509 CLIENT ID:
DRUG TYPE: FUNDING SOURCE: REASON FOR ENDING:

COMP: 677 AUSTIN STATE HOSPITAL DATE FIRST ADDED 20060112
DATE LAST CHANGED 20060112

NAME: BIRCH, BENT J. ID: 11835 COMP: 677 CASE: 0000059509
START DT FUNDING END DATE REAS/DEST COMMENT DRUG TYPE
-----
01-01-06 8 AXIS I LEV 1 DESCRIPTION
29200 SUBSTANCE INDUCED WITHDRAW
AXIS I LEV 2 DESCRIPTION
PRINC DIAG
29200
04-22-02 1 C
COMPONENT TOTAL: 1
> |
```

Note: The COMPONENT TOTAL is the unduplicated number of persons who are receiving or have received new generation medications for the component requested.

The TOTAL CLIENT COUNT is the total number of persons who are receiving or have received new generation medications for all components reported. This number may be duplicated if a person received new generation medications from more than one component during the report period.

This page was intentionally left blank.